Upadacitinib Real-world UPwArds Study in Rheumatoid Arthritis (Part Two)
We join our Editor-in-Chief, Peter Taylor (University of Oxford, Oxford, UK) to discuss a selection of abstracts presented at ACR 2021 investigating JAK inhibitors in the treatment of rheumatoid arthritis.Â
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
In Part 2, we discuss real-world data surrounding the selective JAK1 inhibitor, upadacitinib from the UPwArds study. This study is ongoing and investigating the efficacy and safety of upadacitinib in patients with RA in Germany.Â
The abstract ‘Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study’ (Abstract Number: 0833) was presented at the ACR Convergence, 5-9 November 2021.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
